Gert Heylen Head of Genk Plant

Similar documents
USPSTF Draft Recommendations Investor Call. October 6, 2015

INVESTOR PRESENTATION

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

ELICA 2012 Q3 RESULTS. November 14,

Annual Stockholder Meeting May 30, confidently live life with ease

SCANNER & SERVICES OVERVIEW

MedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy

Cowen Investor Conference March confidently live life with ease

PATENCY-1 Top-Line Results

Creating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016

January 30, 2018 Dow Wilson President and Chief Executive Officer

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

TECHNOLOGY & INNOVATION

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

The acquisition of Fortitech

AGM Presentation For the year to 30 September February 2016

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

34 th Annual J.P. Morgan Healthcare Conference

HILLENBRAND INDUSTRIES INC

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation

Michael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

Forward-Looking Statements

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

N a s d a q : I N S Y

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

GROWTH NOW! Franck Riboud

LivaNova Investor Day

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017

For personal use only

Designing a Smoke-Free Future

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Genomic Health. Kim Popovits, Chairman, CEO and President

GI Dynamics, Inc. Q2 16 Quarterly Shareholder Brief 8/11/16

DuPont Nutrition & Health Craig Binetti, President

M (SAPPHIRE-II)

Investor Presentation. Q April 26, 2018

Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Better Diagnostics for Life

Endesa 1Q 2017 Results 09/05/2017

Harm de Wildt MD TNI

Universal Biosensors, Inc.

Enel Américas 1Q 2018 results

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

For personal use only

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

A world leader in allergy immunotherapy

Diagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015

Acorda Acquisition of Civitas Therapeutics. September 24, 2014

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference

Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective

Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth

Jefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer

Slide 1. Investor presentation. London 5 February 2019

Monogram Announces 2008 Second Quarter Financial Results

Letter to Shareholders SEMI-ANNUAL REPORT 2008

August 7, Q Financial Results

Putting ALK on the right growth trajectory

N A S D A Q : E V F M

Diagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014

Stainless-steel vs Single-use: The Vaccines Perspective

Galvus US NDA Approvable - Overview

Food & Beverages Food for a growing world

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

Fiscal 2019 Annual Meeting of Shareholders December 18, Presentation by Lori Woods, Chief Executive Officer

January 2017 Investor Presentation. confidently live life with ease

Let s share our talents

Investor Presentation

confidently live life with ease Management Presentation

Nomura Healthcare Conference

INVESTOR PRESENTATION

psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company AAO October 25, 2018 NASDAQ: EYPT

Company Profile. FLSmidth Pfister: Dosing to Perfection

Jefferies Healthcare Conference June 6, 2018

Value growth in Human Nutrition & Health

Neovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Merck Pipeline. April 30, 2010

Prostate Cancer Panel. June 2018

AM-125 : Intranasal Betahistine

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

PROACTIVE INVESTOR PRESENTATION

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

DARA Reports Year-End 2012 Financial Results

OncoSec Provides 2018 Business Outlook

Jefferies Healthcare Conference. June 6, 2018

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines

GSK Oncology R&D Update

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Transcription:

Site visit 07 Genk plant June 7 th, 07 Bernard Hallemans Chief Operating Officer Europe Gert Heylen Head of Genk Plant

Disclaimer Forward-Looking Statements This document may contain forward-looking information and statements about Aperam and its subsidiaries. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements may be identified by the words believe, expect, anticipate, target or similar expressions. Although Aperam s management believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Aperam s securities are cautioned that forward-looking information and statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Aperam, that could cause actual results and developments to differ materially and adversely from those expressed in, or implied or projected by, the forwardlooking information and statements. These risks and uncertainties include those discussed or identified in Aperam s filings with the Luxembourg Stock Market Authority for the Financial Markets (Commission de Surveillance du Secteur Financier). Aperam undertakes no obligation to publicly update its forward-looking statements or information, whether as a result of new information, future events, or otherwise.

Site visit 07 Genk plant Aperam Operations Europe

Aperam Operations Europe Material flows between Stainless Europe plants in Europe Production flow of Aperam Stainless & Electrical division in Europe (excluding Precision) Scraps Ferro alloys Scraps Steel plant GENK Slabs Steel plant Châtelet Hot rolling mill Châtelet Slabs/Coils Coils Coils Coils Cold Rolling Mill GENK Cold Rolling Mill ISBERGUES Cold Rolling Mill GUEUGNON Final Products Final Products Final Products C U S T O M E R S Full ownership of the entire flow of the stainless steel production 4

Aperam Operations Europe years of active restructuring for a footprint best in class From 9 to 7 tools by focusing on the most efficient tools and investing a state of the art HAP line in Gueugnon Focusing Capex on the most efficient tools and using swing tools to manage demand variation GENK ISBERGUES GUEUGNON GENK ISBERGUES GUEUGNON HA&P lines HAP HAP RD 79 HA&P lines HAP RD 79 mills 4 4 5 6 mills 4 4 5 6 CA&P/ lines L LCI 0 6 8 CA&P/ lines L LCI 0 6 8 s s Core Markets Capital goods, chemicals & energy Auto, distrib. & st transformation Decoration trim, heat exchanges & white goods Suspension Swing Investment Swing Investment Good loading of most efficient assets benefiting from well-advanced restructuring 5

Site visit 07 Genk plant Aperam Genk

Aperam Genk Genk: One site, two plants located in the heart of Europe European stainless steel industry footprint Genk plant Outokumpu Cold rolling plant Aperam Steel plant Acerinox Terni Steel making Finishing line Ideally located at h drive from German Ruhr area - Europe s best customer market & scrap generation areas 7

Aperam Genk From scrap to finished product Melting Refining Cont. Casting Grinding Steel plant Genk Hot rolling mill Châtelet Cold rolling plant Genk ( ) First A&P Cold Rolling Final A (&P) Finishing (excl. SSC Benelux) With Châtelet HRM, Genk is forming an integrated site to produce stainless steel flat products Finishing synergies have been developed with integrated SSC Benelux nearby the plant 8

Aperam Genk Different worldwide process innovations have been introduced in Genk Steel Plant casting up to m and twin casting Cold Rolling up to m at MKW Most of the process equipments are at state-of-the-art productivity 9

Aperam Genk Leadership journey, launched in 0, leads to high rhythm of operational efficiency improvement Labor productivity evolution in Genk Steel Plant and Cold Rolling Mill 60% Genk plant line productivity evolution - example 0% 40% 0% 0% 00% 00% 80% 0 0 0 04 05 06 07 Ton/act FTE (Ref 0) SP Steel Plant M Cold Rolling Mill Labor productivity improves by 5-7% per year, independent of volume and despite more difficult mix 90% 04 05 06 07 Operational efficiency (t/day) BUL BUL AOD AOD Continuous improvement continues, including on equipment (e.g. AOD, BUL) that is at best-in-class productivity Genk largely contributes to Aperam strategy for competitiveness 0

Aperam Genk An optimal mix between top line and complexity with strong culture of support to the development and growth of top line products Production of the mill Sales evolution of top line products from Genk 70% 60% 50% 40% 0% 0% 0% 00% 0 0 04 05 06 Product Product Product Throughput and capacity optimized thanks to the closed monitoring of mix and Top Line volumes under the constraint of technical complexity Top line product growth is faster than average growth in commodities A well balanced portfolio Top line product development in close collaboration between production and sales teams